Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» AZ's Onglyza has most to lose at FDA safety confab, analysts say
AZ's Onglyza has most to lose at FDA safety confab, analysts say
AZ's Onglyza has most to lose at FDA safety confab, analysts say
Submitted by
admin
on April 9, 2015 - 11:52am
Source:
Fierce Pharma
News Tags:
FDA
Onglyza
diabetes
AstraZeneca
Headline:
AZ's Onglyza has most to lose at FDA safety confab, analysts say
Do Not Allow Advertisers to Use My Personal information
